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Transfusion therapy in the treatment of patients with
b-thalassaemia leads to the development of iron over-
load and subsequent tissue and organ damage if
patients are not chelated effectively. Patients with a
liver iron concentration (LIC) >7 mg Fe⁄g dry weight
(dw) are at an increased risk of progressive organ dys-
function and early death as a result of iron-related
complications (1). The clinical sequelae of transfusional
iron overload may include myocardial disease, liver
ﬁbrosis, perturbed endocrine function and retarded
growth (1). It is therefore important to reduce LIC
below this threshold in patients with LIC ‡7m gF e⁄g
dw and maintain levels in patients with LIC <7 mg
Fe⁄g dw, with effective iron chelation therapy. This
predeﬁned analysis from the prospective, multicentre
ESCALATOR trial (2) evaluates the 2-yr efﬁcacy and
safety of the once-daily oral iron chelator deferasirox
in patients with LIC <7 or ‡7m gF e⁄g dw at enrol-
ment. This manuscript partners the detailed results
from 2.7 yr of the ESCALATOR study (3).
Methods
Study design and deferasirox dosing
The ESCALATOR trial was a prospective, open-label,
multicentre study conducted in seven sites in the Middle
East (2); data reported in this paper are based on
patients from six sites. The seventh site was excluded for
a good clinical practice reason. The ESCALATOR study
design and inclusion⁄exclusion criteria have been
described in full previously (2). The trial consisted of a
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This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-
overloaded patients with b-thalassaemia from the ESCALATOR trial (n = 231). Mean liver iron concentra-
tions (LIC) decreased signiﬁcantly from 21.1 ± 8.2 to 14.2 ± 12.1 mg Fe⁄g dry weight (dw) at 2 yr
(P < 0.001) in patients with LIC ‡7m gF e⁄g dw at baseline; patients with LIC <7 mg Fe⁄g dw maintained
these levels over the treatment period. The proportion of patients with LIC <7 mg Fe⁄g dw increased from
9.4% at core baseline to 39.3% by the end of year 2. The results showed that deferasirox enabled thera-
peutic goals to be achieved, by maintaining LIC in patients with LIC <7 mg Fe⁄g dw at a mean dose of
22.4 ± 5.2 mg⁄kg⁄d and signiﬁcantly reducing LIC in patients with LIC ‡7m gF e⁄g dw at a mean dose of
25.7 ± 4.2 mg⁄kg⁄d, along with a manageable safety proﬁle.
Key words deferasirox; iron chelation therapy; iron overload; b-thalassaemia; efﬁcacy
Correspondence Ali Taher, American University of Beirut Medical Center, PO Box: 11-0236, Riad El Solh 1107 2020, Beirut,
Lebanon. Tel: + 961 1 350000 ext 5392; Fax: +96 1 1 370814; e-mail: ataher@aub.edu.lb
Accepted for publication 3 June 2011 doi:10.1111/j.1600-0609.2011.01661.x
Re-use of this article is permitted in accordance with the Terms and
Conditions set out at http://wileyonlinelibrary.com/onlineopen#Online
Open_Terms
ORIGINAL ARTICLE
European Journal of Haematology 87 (349–354)
ª 2011 John Wiley & Sons A/S 3491-yr core study, after which patients were eligible to enter
into a 2-yr extension study. In the core study, patients
started on deferasirox 20 mg⁄kg⁄d except for three
patients who received an initial dose of 10 mg⁄kg⁄d,
which was subsequently increased to 20 mg⁄kg⁄d based
on protocol amendment. Dose adjustments by
5⁄10 mg⁄kg⁄d were performed based on serum ferritin
trends and safety markers during the core and extension.
Dose increases to >30 mg⁄kg⁄d were permitted in the
extension study (range 0–40 mg⁄kg⁄d).
Assessments
Efﬁcacy was assessed based on change from core base-
line in LIC and serum ferritin levels after 2 yr of treat-
ment (i.e. 1 yr core + year 1 of extension). Efﬁcacy is
not presented for year 2 of the extension because of the
observed decline in the number of patients remaining
on study during this period, once deferasirox became
available commercially. (Such patients were noted as
study completers but were removed from study assess-
ments after transferring to commercially available defer-
asirox.) Patients with a core baseline LIC of
‡7m gF e⁄g dw had a therapeutic goal of LIC reduc-
tion, while in patients with a baseline LIC of 2 to <7
mg Fe⁄g dw, the therapeutic goal was maintenance.
LIC was determined by biopsy at core baseline and
after 1 yr and by magnetic resonance imaging after
2 yr. Serum ferritin levels were assessed at baseline and
every 4 wk. Safety and tolerability were evaluated
across the entire study period by monitoring the inci-
dence and type of adverse events (AEs) and by assess-
ing routine laboratory parameters. Left ventricular
ejection fraction (LVEF) measurements by echocardio-
gram scan were also recorded. Proteinuria was assessed
using second void morning urine and deﬁned as above
an upper limit of normal (ULN) of 0.149 g⁄L.
Statistical methods
Statistical methods used were as described previously for
the core study (2). Only patients who enrolled for the
extension study are included in this analysis. The efﬁcacy
analyses are presented for the intent-to-treat population,
which includes all patients who enrolled into the exten-
sion study, irrespective of whether they received study
drug during the extension. The safety population for
which safety data are analysed includes all patients who
entered the extension study and received at least one
dose of deferasirox.
Results
Patient characteristics and dose adjustments
Of 233 patients who completed the core study (2), all
were enrolled to continue into the extension study and
231 received at least one dose of deferasirox during the
extension. Two patients entered the extension study but
did not receive deferasirox and had LIC ‡7m gF e⁄gd w
at core baseline. Of the patients who received at least
one deferasirox dose during the extension study, 22 had
Table 1 Demographics at core baseline of
patients who received at least one deferasirox
dose in the extension study
Baseline LIC
<7 mg Fe⁄gd w
(n=22)
Baseline LIC
‡7m gF e⁄gd w
(n=209)
Mean age ± SD, yr 9.4 ± 4.3 13.4 ± 7.1
Patients aged 2 to <16 yr, n (%) 20 (90.9) 142 (67.9)
Patients aged ‡16 yr, n (%) 2 (9.1) 67 (32.1)
Female⁄male, n 9 : 13 105 : 104
History of hepatitis B and⁄or C, n (%) 2 (9.1) 69 (33.0)
Splenectomy, n (%) 4 (18.2) 89 (42.6)
Previous chelation therapy, n (%)
DFO monotherapy 20 (90.9) 164 (78.5)
Deferiprone monotherapy 0 4 (1.9)
DFO + deferiprone 2 (9.1) 41 (19.6)
Median duration of previous chelation
therapy (range), yr
1
6.0 (0.3–15.6) 6.7 (0.1–21.0)
Mean number of transfusion sessions
in the year prior to study entry ± SD
15.2 ± 3.1 15.1 ± 4.4
Mean amount transfused in the year
prior to study entry ± SD, mL⁄kg
165 ± 42 173 ± 70
Mean baseline LIC ± SD, mg Fe⁄g dw 4.5 ± 1.8 21.1 ± 8.2
2
Median baseline serum ferritin (range), ng⁄mL 1921 (914–5696) 3621 (998–25 008)
2
1Patients with LIC <7 mg Fe⁄gd wn=16, patients with LIC ‡7m gF e⁄gd wn=154.
2n=211.
SD, standard deviation; DFO, deferoxamine; LIC, liver iron concentrations.
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at core baseline (Table 1). One patient who had a LIC
value <7 mg Fe⁄g dw at baseline did not undergo liver
biopsy at the end of the core study.
Deferasirox dosing and iron intake
During the core and extension, mean deferasirox dose in
the LIC <7 and ‡7m gF e⁄g dw cohorts was 22.4 ± 5.2
and 25.7 ± 4.2 mg⁄kg⁄d over median treatment periods
of 123.0 and 143.4 wk, respectively. Sixteen patients
(72.7%) with baseline LIC <7 mg Fe⁄g dw and 190
patients (90.9%) with baseline LIC ‡7m gF e⁄g dw had
dose increases during the study. The median time to ﬁrst
dose increase was 32 wk (range 8–101) in the LIC
<7 mg Fe⁄g dw cohort and 39 wk (range 3–132) in the
‡7m g F e⁄g dw cohort. The numbers of patients who
had dose decreases (one of 22 [4.5%]; 10 of 209 [4.8%])
and dose interruptions owing to AEs and laboratory
abnormalities (two of 22 [9.1%]; 26 of 209 [12.4%]) were
comparable among the LIC <7 and ‡7m g F e⁄gd w
cohorts, respectively. By the end of the extension study,
two patients (9.1%) in the LIC <7 mg Fe⁄g dw cohort
and 54 patients (25.8%) in the LIC ‡7m g F e⁄gd w
cohort were receiving 40 mg⁄kg⁄d deferasirox. The ﬁnal
doses received by patients in the LIC <7 and ‡7m g
Fe⁄g dw cohorts are detailed in Table 2. Mean iron
intake during the core and extension studies was also
comparable in the LIC <7 (0.34 ± 0.07 mg⁄kg⁄d) and
‡7m gF e⁄g dw (0.33 ± 0.10 mg⁄kg⁄d) cohorts.
Efﬁcacy
In the LIC <7 mg Fe⁄g dw cohort, mean LIC remained
stable (mean change of )0.2 ± 3.0 mg Fe⁄g dw;
Fig. 1A) over 2 yr (core baseline: 4.5 ± 1.8 mg Fe⁄g dw;
at 2 yr 4.3 ± 2.7 mg Fe⁄g dw). In the LIC ‡7m gF e⁄g
dw cohort, mean LIC decreased signiﬁcantly from
21.1 ± 8.2 mg Fe⁄g dw at core baseline to
14.2 ± 12.1 mg Fe⁄g dw at 2 yr (overall mean change
)7.2 ± 9.6 mg Fe⁄g dw, P < 0.001; Fig. 1A). The pro-
portion of patients with LIC <7 mg Fe⁄g dw increased
from 22⁄233 (9.4%) at core baseline to 61⁄233 (26.2%)
at the end of 1 yr and to 83⁄211 (39.3%) at the end of
year 2. A similar pattern of response was observed with
serum ferritin levels (Fig. 1B). A summary of the number
of patients with LIC <7, 7 to <10 and ‡10 mg Fe⁄gd w
at core baseline, at the end of 1 yr and at the end of
2 yr, by baseline LIC category, is shown in Table 3.
Median serum ferritin levels were maintained around
core baseline levels (1921 ng⁄mL) in the LIC
<7 mg Fe⁄g dw cohort (1915 ng⁄mL after 2 yr, median
change )145 ng⁄mL; P = 0.418) and decreased signiﬁ-
cantly in the LIC ‡7m gF e⁄g dw cohort (3621 ng⁄mL at
core baseline, 2398 ng⁄mL after 2 yr, median change
)1052 ng⁄mL; P < 0.0001). A signiﬁcant correlation
between serum ferritin and LIC was observed at core
baseline (r = 0.51; P < 0.001), at the end of 1 yr
(r = 0.65; P < 0.001) and at the end of 2 yr (r = 0.66;
P < 0.001, Fig. 2). In order to investigate whether any
baseline characteristic could be used to identify patients
Table 2 Final deferasirox dosing for patients who received at least
one deferasirox dose in the extension study
Patient ﬁnal dose in
mg⁄kg⁄d, n (%)
Baseline LIC
<7 mg Fe⁄gd w
(n=22)
Baseline LIC
‡7m gF e⁄gd w
(n=209)
5 0 (0) 0 (0)
10 0 (0) 1 (0.5)
15 1 (4.5) 3 (1.4)
20 6 (27.3) 28 (13.4)
25 3 (13.6) 20 (9.6)
30 4 (18.2) 56 (26.8)
35 4 (18.2) 33 (15.8)
40 2 (9.1) 54 (25.8)
Prematurely discontinued 2 (9.1) 14 (6.7)
LIC, liver iron concentrations.
A
B
Figure 1 (A) Mean liver iron concentrations (LIC) ± SD and (B) med-
ian serum ferritin ± 25th⁄75th percentiles during deferasirox treat-
ment in all patients enrolled in the extension study, by LIC at core
baseline. Whiskers represent minimum and maximum values.
*P < 0.001 at end of 2 yr vs. core baseline.
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univariate analysis of baseline characteristics were per-
formed. Only LIC and serum ferritin were signiﬁcantly
different (P < 0.0001 for both) at baseline in patients
with EOS LIC <7 or ‡7m gF e⁄g dw (Table 4).
Discontinuations and safety
Twenty patients (90.9%) in the baseline LIC <7 mg
Fe⁄g dw cohort and 196 patients (92.9%) in the baseline
LIC ‡7m gF e⁄g dw cohort completed the study. Rea-
sons for discontinuation were as follows: loss to follow-
up (n = 2, 9.1% and n = 6, 2.8%), AEs (0% and
n = 3, 1.4%), death (0% and n = 3, 1.4%), protocol
violation (0% and n = 2, 0.9%) and consent withdrawal
(0% and n=1, 0.5%) in the LIC <7 and ‡7m gF e⁄g
dw cohorts, respectively. Of the three deaths reported
during the study, these were attributed to respiratory
failure and as a result of cerebral and subarachnoid
haemorrhage; none were considered to be related to
study drug. AEs considered by the investigator to be
related to deferasirox were reported in 100 patients
(43.3%) in the core study. Overall, drug-related AEs
were less common in the extension study (55 patients;
23.8%) vs. the core study (100 patients; 43.3%)
(Table 5). Serious AEs were reported in two patients
(9.1%) in the LIC <7 mg Fe⁄g dw cohort and
24 patients (11.5%) in the LIC ‡7m gF e⁄g dw cohort.
These were considered to be drug-related in three
patients, all of whom were in the LIC ‡7m gF e⁄gd w
cohort (peptic ulcer perforation, increased serum creati-
nine levels and cholestatic jaundice).
LVEF at core baseline was above the lower limit of
normal (4) in both LIC cohorts and increased in both
during deferasirox treatment. Mean LVEF increased
non-signiﬁcantly from 63.2 ± 6.6% to 67.8 ± 9.5%
(mean absolute increase 4.3 ± 13.7%) in the LIC
<7 mg Fe⁄g dw cohort and improved signiﬁcantly in the
LIC ‡7m g F e⁄g dw cohort (65.4 ± 6.8% to
68.3 ± 7.7%; mean absolute increase 2.1 ± 8.1%;
Table 3 Patients with LIC <7, 7 to <10 and ‡10 mg Fe/g dw at core
baseline, at the end of 1 yr and at the end of 2 yr, by baseline LIC cat-
egory
Baseline LIC
LIC category, mg Fe⁄gd w[ n (%)]
Total
<7 mg
Fe⁄gd w
7 to <10 mg
Fe⁄gd w
‡10 mg
Fe⁄gd w
Core baseline
<7 mg Fe⁄g dw 21 (95.5) 1 (4.5)
1 0 (0.0) 22 (9.4)
‡7m gF e⁄g dw 2 (0.9)
1 18 (8.5) 191 (90.5) 211 (90.6)
Total 23 (9.9) 19 (8.2) 191 (82.0) 233 (100.0)
End of year 1
<7 mg Fe⁄g dw 18 (81.8) 3 (13.6) 1 (4.5) 22 (9.4)
‡7m gF e⁄g dw 43 (20.4) 27 (12.8) 141 (66.8) 211 (90.6)
Total 61 (26.2) 30 (12.9) 142 (60.9) 233 (100.0)
End of year 2
<7 mg Fe⁄g dw 15 (88.2) 1 (5.9) 1 (5.9) 17 (8.1)
‡7m gF e⁄g dw 68 (35.1) 25 (12.9) 101 (52.1) 194 (91.9)
Total 83 (39.3) 26 (12.3) 102 (48.3) 211 (100.0)
LIC, liver iron concentrations; MRI, magnetic resonance imaging.
1Baseline LIC categories were assessed using liver biopsy. LIC cate-
gories during the study were assessed by MRI. This resulted in the
classiﬁcation of one patient with a baseline LIC <7 mg Fe⁄g dw with
an LIC category of 7 to <10 mg Fe⁄g dw and classiﬁcation of two
patients with a baseline LIC ‡7m gF e⁄g dw with an LIC category of
<7 mg Fe⁄g dw.
A
B
C
Figure 2 Scatter plot of serum ferritin and liver iron concentrations at
(A) core baseline; (B) end of 1 yr; and (C) end of 2 yr.
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baseline and above the ULN were observed in four
patients (18.2%) with baseline LIC <7 mg Fe⁄gd w
and in four (1.9%) patients with baseline LIC
‡7m gF e⁄g dw. One patient (4.5%) in the LIC <7 mg
Fe⁄g dw cohort and seven patients (3.3%) in the LIC
‡7m g F e⁄g dw cohort had alanine aminotransferase
(ALT) levels >10· ULN on two consecutive occasions;
core baseline levels were elevated in one and four
patients, respectively. Mean ALT levels decreased in the
LIC ‡7m g F e⁄g dw cohort ()27.7 ± 47.4 U⁄L,
P < 0.0001; baseline 65.4 ± 46.1 U⁄L) and remained
stable in the LIC <7 mg Fe⁄g dw cohort
(+6.7 ± 47.0 U⁄L; baseline 35.2 ± 43.2 U⁄L) at the
end of the extension study.
Discussion
Patients enrolled in the ESCALATOR study were char-
acterised by a very high iron burden, despite receiving
prior chelation therapy; most patients (210⁄233 patients;
90.1%) had LIC of ‡7m g F e⁄g dw at core baseline.
Markers of iron overload at core baseline, including
serum ferritin levels and LIC (see Table 1), were much
greater than levels known to be associated with signiﬁ-
cant negative outcomes (serum ferritin >2500 ng⁄mL
and LIC >15 mg Fe⁄g dw) (1, 5) and hence what is
generally clinically desirable. This suggests that previous
chelation regimens were suboptimal in these patients and
were unable to maintain iron levels consistently below
these thresholds.
In line with study objectives, treatment with deferasi-
rox over 2 yr was able to maintain iron levels in patients
with baseline LIC <7 mg Fe⁄g dw and to reduce iron
load in patients with baseline LIC ‡7m gF e⁄g dw. In
Table 4 Analysis of baseline characteristics
in patients with EOS LIC <7 mg Fe⁄gd wo r
‡7m gF e⁄gd w
Characteristic at baseline EOS LIC
<7 mg Fe⁄gd w
(n = 112)
EOS LIC
‡7m gF e⁄gd w
(n = 121) P-value
Mean age ± SD, yr 13.7 ± 7.2 12.5 ± 6.7 0.214
Female⁄male, n 54 : 58 60 : 61 0.834
History of hepatitis B and⁄or C, n (%) 28 (25.0) 43 (35.5) 0.081
Splenectomy, n (%) 45 (40.2) 50 (41.3) 0.859
Previous chelation therapy, n (%)* 0.108
DFO monotherapy 87 (77.7) 99 (81.8) –
Deferiprone monotherapy 4 (3.6) 0 (0.0) –
DFO + deferiprone 21 (18.8) 22 (18.2) –
Median duration of previous chelation
therapy (range), yr
1
7.9 (0.3–21.0) 6.5 (0.1–20.6) 0.228
Mean number of transfusion sessions
in the year prior to study entry ± SD
2
14.6 ± 3.8 15.6 ± 4.6 0.393
Mean amount transfused in the year
prior to study entry ± SD, mL⁄kg
3
167.1 ± 65.0 175.5 ± 70.4 0.471
Mean baseline LIC ± SD, mg Fe⁄g dw 14.9 ± 7.9 23.9 ± 8.3 <0.0001
Median baseline serum ferritin (range), ng⁄mL 2553 (914–7519) 4299 (1154–25 008) <0.0001
SD, standard deviation; DFO, deferoxamine; EOS, end-of-study; ITT, intent-to-treat; LIC, liver
iron concentrations. LIC at EOS is based on last observation carried forward (LOCF) on the ITT
population.
*P-value calculated for patients receiving previous chelation therapy with any of DFO, deferi-
prone or DFO⁄deferiprone.
1Patients with LIC <7 mg Fe⁄gd wn=69, patients with LIC ‡7m gF e⁄gd wn=102.
2Patients with LIC <7 mg Fe⁄gd wn=101, patients with LIC ‡7m gF e⁄gd wn=118.
3Patients with LIC <7 mg Fe⁄gd wn=93, patients with LIC ‡7m gF e⁄gd wn=116.
Table 5 Overall and most common investigator-assessed drug-related
AEs (‡5% in either cohort) in patients who received at least one def-
erasirox dose in the extension study, by LIC at core baseline
Adverse event, n (%)
Core baseline LIC, mg Fe⁄gd w
<7 (n=22) ‡7( n=209)
Core Extension Core Extension
Any AE 11 (50.0) 6 (27.3) 89 (42.6) 49 (23.4)
Vomiting 2 (9.1) 2 (9.1) 18 (8.6) 12 (5.7)
Increased serum
creatinine
1 (4.5) 1 (4.5) 8 (3.8) 13 (6.2)
Increased ALT 3 (13.6) 3 (13.6) 10 (4.8) 13 (6.2)
Rash 3 (13.6) 0 15 (7.2) 2 (1.0)
Nausea 0 0 14 (6.7) 4 (1.9)
Increased AST 2 (9.1) 0 4 (1.9) 2 (1.0)
Proteinuria 2 (9.1) 0 4 (1.9) 1 (0.5)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AEs,
adverse events; LIC, liver iron concentrations.
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in iron burden from core baseline after 2 yr of deferasi-
rox treatment. Given the relatively long median time to
ﬁrst dose increase in both cohorts, it is important to note
that more rapid dose escalations may be required in
order to achieve therapeutic goals over a shorter time
frame. This is particularly important when reduction in
iron burden is desired such as in the LIC ‡7m gF e⁄gd w
cohort. Although the patient numbers in the LIC
<7 mg Fe⁄g dw cohort are low, the results for both
cohorts are consistent with a subanalysis of the large
EPIC study in which patients with LIC <7 (n=71)
and ‡7m gF e⁄gd w( n=303) experienced a stabilisation
or reduction in LIC, respectively, when treated with
mean actual deferasirox doses of 20 and 27 mg⁄kg⁄d
over a 1-yr period (6).
During this study, deferasirox was well tolerated with
a clinically manageable safety proﬁle. Most AEs were
mild-to-moderate in nature and were consistent with AEs
reported in the core trial (2). Mean ALT levels decreased
signiﬁcantly in the LIC ‡7m g F e⁄g dw cohort but
remained unchanged in the LIC <7 mg Fe⁄g dw cohort,
reﬂecting the changes in LIC and serum ferritin levels.
Overall, drug-related AEs were less common in the
extension study compared with the core study. There was
no clear trend in the type or frequency of drug-related
AEs between the LIC <7 and ‡7m gF e⁄g dw cohorts.
In conclusion, appropriate deferasirox dosing was able
to maintain or reduce iron burden in patients with
b-thalassaemia in line with therapeutic goals.
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